139 related articles for article (PubMed ID: 12935991)
1. Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD).
Castagna L
Haematologica; 2003 Aug; 88(8):ELT28; author reply ELT29. PubMed ID: 12935991
[No Abstract] [Full Text] [Related]
2. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease.
Busca A; Locatelli F; Marmont F; Audisio E; Falda M
Haematologica; 2003 Jul; 88(7):837-9. PubMed ID: 12857569
[No Abstract] [Full Text] [Related]
3. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
[TBL] [Abstract][Full Text] [Related]
4. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
Basara N; Blau WI; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Bone Marrow Transplant; 1998 Jul; 22(1):61-5. PubMed ID: 9678797
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of mycophenolate mofetil.
Basara N; Fauser AA
Bone Marrow Transplant; 2000 Dec; 26(12):1362-3. PubMed ID: 11223981
[No Abstract] [Full Text] [Related]
7. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.
Takami A; Mochizuki K; Okumura H; Ito S; Suga Y; Yamazaki H; Yamazaki M; Kondo Y; Asakura H; Nakao S
Int J Hematol; 2006 Jan; 83(1):80-5. PubMed ID: 16443558
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of mycophenolate mofetil: a response.
Busca A; Locatelli F; Falda M
Bone Marrow Transplant; 2001 Apr; 27(8):892. PubMed ID: 11477451
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.
Basara N; Blau WI; Kiehl MG; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Transplant Proc; 1998 Dec; 30(8):4087-9. PubMed ID: 9865306
[No Abstract] [Full Text] [Related]
10. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
Dvorak CC; Callard E; Agarwal R
Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
[No Abstract] [Full Text] [Related]
11. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.
Lopez F; Parker P; Nademanee A; Rodriguez R; Al-Kadhimi Z; Bhatia R; Cohen S; Falk P; Fung H; Kirschbaum M; Krishnan A; Kogut N; Molina A; Nakamura R; O'Donnell M; Popplewell L; Pullarkat V; Rosenthal J; Sahebi F; Smith E; Snyder D; Somlo G; Spielberger R; Stein A; Sweetman R; Zain J; Forman S
Biol Blood Marrow Transplant; 2005 Apr; 11(4):307-13. PubMed ID: 15812396
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil-induced colitis with graft versus host disease-like features in a liver transplant recipient.
Patra S; Vij M; Sukanya B; Kapoor D
Indian J Pathol Microbiol; 2012; 55(4):506-8. PubMed ID: 23455789
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.
Basara N; Kiehl MG; Blau W; Römer E; Bischoff M; Schmetzer B; Kirsten D; Günzelmann S; Fauser AA
Transplant Proc; 2001 May; 33(3):2121-3. PubMed ID: 11377471
[No Abstract] [Full Text] [Related]
14. [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
Mori M; Muroi K; Matsuyama T; Oka S; Ono Y; Yamamoto C; Uesawa M; Okabe H; Matsu H; Tatara R; Kikuchi Y; Fujiwara S; Kikuchi S; Sato K; Ueda M; Toshima M; Ozaki K; Takatoku M; Nagai T; Ozawa K
Rinsho Ketsueki; 2007 Aug; 48(8):624-31. PubMed ID: 17867298
[TBL] [Abstract][Full Text] [Related]
15. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
Furlong T; Martin P; Flowers ME; Carnevale-Schianca F; Yatscoff R; Chauncey T; Appelbaum FR; Deeg HJ; Doney K; Witherspoon R; Storer B; Sullivan KM; Storb R; Nash RA
Bone Marrow Transplant; 2009 Dec; 44(11):739-48. PubMed ID: 19377515
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
[TBL] [Abstract][Full Text] [Related]
17. Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?
Levine JE
Pediatr Transplant; 2015 Sep; 19(6):582-3. PubMed ID: 26215797
[No Abstract] [Full Text] [Related]
18. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
19. [Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].
Miyoshi T; Kawano-Yamamoto C; Nagashima T; Nagai T; Komatsu N; Muroi K; Ozawa K
Rinsho Ketsueki; 2003 Sep; 44(9):968-70. PubMed ID: 14577320
[TBL] [Abstract][Full Text] [Related]
20. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]